AbDrop: Fully Human Antibodies Discovery: Increased Diversity, Validated Candidates in Just 3 Months! 詳しくはこちら

New Small-Scale Expression Packages: RushMab- Ready in just 8 days! 詳しくはこちら

Biointron Insights: Antibody Industry Trends (Q2 2026 Insights, Trends & Analysis) 詳しくはこちら

Biointron Insights: Antibody Industry Trends (Q1 2026 Insights, Trends & Analysis) 詳しくはこちら

Biointron Insights: Antibody Industry Report (Q2 2025 Insights, Trends & Analysis) 詳しくはこちら

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis) 詳しくはこちら

Biointron x Antibody Society Webinar: Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab and High-Throughput Single B Cell Screening 詳しくはこちら

Biointron - リコンビナント抗体発現/開発サービス

Antibody Antibody Antibody

AI-Ready Antibody Data Generated in Days

RushData

Delivering structured, high-quality datasets that help you move faster from antibody discovery to confident decision-making.

詳しくはこちら

リコンビナント抗体発現

週間2で作業完了

遺伝子配列から精製された抗体まで

詳しくはこちら

Accelerating
Your Antibody Discovery

詳しくはこちら

AbDrop: Discovery Fully Human Antibodies

Fully Human
Antibody Discovery

Rapid Generation of High-Quality, Fully Human Antibodies: Increased Diversity, Validated Candidates in Just 3 Months!

詳しくはこちら

アフィニティ・
マチュレーション

CDR領域におけるノーバイアス部位飽和突然変異誘発法

詳しくはこちら

VHH抗体開発

ユニークなバインダーを保証

詳しくはこちら

二重特異性
抗体発現

すべてのBsAbのフォーマットをカスタマイズ可能

詳しくはこちら

カスタムサービス&プロダクト品

About Us

  • 0 +
    Years of Experience
  • 0 +
    Employees
  • 0 +
    Companies Served Globally
  • 0 +
    Antibodies Delivered Annually

Why you should choose us

  • 先進的抗体ソリューション

    私たちは抗体の発現、開発、最適化に注力し、先進的な自動化生産ラインを持ち、競争力のある価格と効率的なリードタイムを提供できます。

  • ユニークな細胞株を商品化

    私たちはECACCからライセンスされたCHOK1BN細胞株の商業化に関する排他的な再ライセンス権を保有しています。

  • グローバルな協力体制

    私たちの2,000+のグローバルなバイオテクノロジー企業や製薬企業とのパートナーシップになり、そして、国際的な臨床段階での共同の進歩と結びついています。

  • 信頼と所有権

    私たちは、お客様に提供した抗体の所有権を守り、機密情報の保持をお約束します。

Antibody

Biointronとの協力により、最適化された効率的で経済的かつ最高水準のカスタム抗体ソリューションを提供します。

About Biointron

Biointronは2012年に設立され、ISO 9001:2015認証を取得し、抗体の発見、開発、最適化分野のハイテク企業です。


Biointronは、リーディングな高スループットの再組み合わせ抗体/タンパク質発現および開発サービスプロバイダーです。遺伝子配列から抗体の精製まで、わずか2週間で行います。Biointronは、1700+のバイオテクノロジー企業や製薬企業に数万種類の再組み合わせ抗体を提供しています。

詳しくはこちら 詳しくはこちら

お客様からの声

Biointronのパートナーやクライアントから、Biointronの専門知識がもたらす変革のインパクトについて学びましょう。

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

ニュース一覧

Biointron Insights: Antibody Industry Trends (Q2 2026 Insights, Trends & Analysis)

Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, six novel monoclonal antibody drugs have received first approval.

2026-06-30
Integrating Developability Screening Earlier in Antibody Discovery

For an antibody candidate, strong target binding is only part of the path toward a successful therapeutic. A molecule can show high affinity and selectivity yet encounter problems later because of poor stability, low expression, aggregation, non-specific binding, or other unfavorable biophysical properties.

2026-07-17
VHH-Based Biosensors: Precision Tools for High-Sensitivity Detection

Explore VHH-based biosensors for high-sensitivity detection using nanobodies in electrochemical, SPR, and optical diagnostic platforms.

2026-07-15
Biointron Launches RushData, an Integrated High-Throughput Platform for AI-Driven Antibody Discovery

Biointron, a leading contract research organization specializing in antibody discovery, expression, and optimization for global biotechnology and pharmaceutical companies, today announced the launch of RushData, a new integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery.

2026-06-16
Biointron Launches RushMab™ Packages to Deliver Purified Antibodies in 10 Days

Biointron, a contract research organization specializing in antibody discovery and production services with offices located in Cambridge, Massachusetts, and Piscataway, New Jersey, has released Small-Scale Antibody Expression Packages under the RushMab brand, compressing the wait to as few as 4 days for transfection-grade expression plasmids and 10 days for purified, quality-controlled antibody material.

2026-05-29
Biointron Launches Comprehensive Antibody Developability Assessment Platform to Accelerate Biologic Drug Discovery

Biointron launched its Antibody Developability Assessment Services to help drug developers catch potential problems before they turn into expensive failures. The platform combines high-throughput antibody production with a full panel of tests that check whether candidates can be manufactured at scale and remain stable throughout their shelf life, with results delivered in three to five days per assay.

2026-04-15
Immunology 2026

Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228

AACR Annual Meeting 2026

Time: April 17 – 22, 2026
Location: San Diego, CA
Booth: #4154

BIO Korea 2026

Time: April 28 – 30, 2026
Location: Seoul, South Korea

当サイトでは、お客様の利便性向上のためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。